drugset / Trial / NCT02266498

Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects

NCT02266498

Phase 1 Completed 8 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To assess the effect of a breakfast (40 g fat) on single dose pharmacokinetics of a 2.5 mg BIBB 515 dose in capsules as well as the tolerability of BIBB 515 BS capsules

Timeline

Start
1998-06
Primary completion
1998-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBB 515 BS Unknown 2.5 mg Oral

Indications

No indication recorded.